	M37.2 - TICAGRELOR (<i>BRILINTA</i>)	
	Version date: 2025-02-15	Effective date: 2025-04-30 (07:00)

INDICATIONS

- Known or suspected ST elevation myocardial infarction (STEMI) if patient is going directly to primary coronary intervention (PCI)

WARNINGS

ABSOLUTE CONTRAINDICATIONS:

- Hypersensitivity to ticagrelor
- Patient may be candidate for fibrinolysis
- Active major bleeding

ADMINISTRATION

This requires authorization from the Code-STEMI physician / VECTRS emergency physician (or designate)

ORAL

PCP / ICP / ACP



ADULTS:

- Administer 2 tablets (180 mg) as directed by the Code-STEMI physician

NOTES

LINKS

- E04 - Acute Coronary Syndrome & STEMI & NSTEMI-ACS

APPROVED BY	
	
Provincial Medical Director	Provincial Associate Medical Director

VERSION CHANGES (refer to X08 for change tracking)
<ul style="list-style-type: none">• Addition of advanced work scope